Douglas S. Ingram - 03 Nov 2023 Form 4 Insider Report for Sarepta Therapeutics, Inc. (SRPT)

Role
President & CEO, Director
Signature
/s/ Ryan Brown, as Attorney-in-Fact for Douglas S. Ingram
Issuer symbol
SRPT
Transactions as of
03 Nov 2023
Net transactions value
+$2,001,800
Form type
4
Filing time
06 Nov 2023, 08:00:10 UTC
Previous filing
01 Jun 2023
Next filing
05 Jun 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SRPT Common Stock Purchase $792,064 +10,081 +2.8% $78.57 375,163 03 Nov 2023 Direct F1
transaction SRPT Common Stock Purchase $881,482 +11,060 +2.9% $79.70 386,223 03 Nov 2023 Direct F2
transaction SRPT Common Stock Purchase $312,002 +3,884 +1% $80.33 390,107 03 Nov 2023 Direct F3
transaction SRPT Common Stock Purchase $16,252 +200 +0.05% $81.26 390,307 03 Nov 2023 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $78.03 to $79.02, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
F2 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $79.05 to $80.05, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
F3 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $80.08 to $80.96, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.